Founded in 2007, Vivacy burst onto the injectable medical devices market with an innovative product, sold to plastic surgeons and dermatologists in France and exported to around sixty countries, including Russia, Ukraine and Brazil, via a network of distributors. Its flagship product, STYLAGE, has met with considerable commercial success, winning a high market share in competition against major global laboratories.
We invested in Vivacy in late 2012, as a minority shareholder, to support its management with the structuring of the company, which was developing fast and had ambitious development plans, particularly in the United States and China.
In 2015, after some years of healthy growth, we were approached to sell our stake to make room for Bloomage Biotechnology Corp. Ltd, which was offering to help the country establish itself on the Chinese market.
Evolution of turnover
Type of investment
Changes in the number of employees
Sector of activity